REGULATION OF BINDING-PROTEINS FOR INSULIN-LIKE GROWTH-FACTORS (IGF) IN HUMANS - INCREASED EXPRESSION OF IGF BINDING PROTEIN-2 DURING IGF-I TREATMENT OF HEALTHY-ADULTS AND IN PATIENTS WITH EXTRAPANCREATIC TUMOR HYPOGLYCEMIA

被引:189
作者
ZAPF, J [1 ]
SCHMID, C [1 ]
GULER, HP [1 ]
WALDVOGEL, M [1 ]
HAURI, C [1 ]
FUTO, E [1 ]
HOSSENLOPP, P [1 ]
BINOUX, M [1 ]
FROESCH, ER [1 ]
机构
[1] HOP TROUSSEAU,INSERM,U142,F-75571 PARIS 12,FRANCE
关键词
extrapancreatic tumor hypoglycemia; IGF binding proteins; IGF I treatment;
D O I
10.1172/JCI114797
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Insulin-like growth factors (IGFs) in blood form two complexes with specific binding proteins (BPs): a large, growth hormone (GH)-dependent complex with restricted capillary permeability, and a smaller complex, inversely related to GH, with high turnover of its IGF pool and free capillary permeability. The distribution of BPs and of IGFs I and II between these complexes was studied in sera from healthy adults treated with IGF I or/and GH and from patients with extrapancreatic tumor hypoglycemia. Like GH, IGF I administration raises IGF I and two glycosylation variants of IGFBP-3 in the large complex, but unlike GH drastically reduces IGF II. During IGF I infusion, IGFBP-3 appears in the small complex whose IGFBP-2 and IGF I increase three- to five-fold and five-fold, respectively. GH treatment, associated with elevated insulin levels, suppresses IGFBP-2 and inhibits its increase owing to infused IGF I. The small complex of tumor sera contains increased amounts of IGFBP-2 and -3, and two- to three-fold elevated IGF II. Conclusions: low GH and/or insulin during IGF I infusion and in extrapancreatic tumor hypoglycemia enhance expression of IGFBP-2 and favor partition of IGFBP-3 into the small complex. Free capillary passage and high turnover of its increased IGF I or II pools may contribute to compensate for suppressed insulin secretion during IGF I infusion or to development of tumor hypoglycemia.
引用
收藏
页码:952 / 961
页数:10
相关论文
共 49 条
[1]   ON THE NOMENCLATURE OF THE IGF BINDING-PROTEINS [J].
BALLARD, J ;
BAXTER, R ;
BINOUX, M ;
CLEMMONS, D ;
DROP, S ;
HALL, K ;
HINTZ, R ;
RECHLER, M ;
RUTANEN, E ;
SCHWANDER, J .
ACTA ENDOCRINOLOGICA, 1989, 121 (05) :751-752
[2]  
BAXTER RC, 1989, J BIOL CHEM, V264, P11843
[3]   GROWTH HORMONE-DEPENDENT INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING-PROTEIN FROM HUMAN-PLASMA DIFFERS FROM OTHER HUMAN IGF BINDING-PROTEINS [J].
BAXTER, RC ;
MARTIN, JL ;
TYLER, MI ;
HOWDEN, MEH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 139 (03) :1256-1261
[4]   STRUCTURE OF THE MR 140,000 GROWTH HORMONE-DEPENDENT INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN COMPLEX - DETERMINATION BY RECONSTITUTION AND AFFINITY-LABELING [J].
BAXTER, RC ;
MARTIN, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (18) :6898-6902
[5]   CLONING, SEQUENCE-ANALYSIS AND EXPRESSION OF A CDNA-ENCODING A NOVEL INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN (IGFBP-2) [J].
BINKERT, C ;
LANDWEHR, J ;
MARY, JL ;
SCHWANDER, J ;
HEINRICH, G .
EMBO JOURNAL, 1989, 8 (09) :2497-2502
[6]   INSULIN-LIKE GROWTH-FACTOR (IGF) AND IGF-BINDING PROTEINS - COMPARISON OF HUMAN-SERUM AND LYMPH [J].
BINOUX, M ;
HOSSENLOPP, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (03) :509-514
[7]   REGULATION OF HEPATIC EXPRESSION OF IGF-I AND FETAL IGF BINDING-PROTEIN MESSENGER-RNA IN STREPTOZOTOCIN-DIABETIC RATS [J].
BONISCHNETZLER, M ;
BINZ, K ;
MARY, JL ;
SCHMID, C ;
SCHWANDER, J ;
FROESCH, ER .
FEBS LETTERS, 1989, 251 (1-2) :253-256
[8]  
BONISCHNETZLER M, 1990, IN PRESS MOL ENDOCRI
[9]  
BROWN AL, 1989, J BIOL CHEM, V264, P5148
[10]   SERUM HALF-LIFE OF SOMATOMEDIN ACTIVITY - EVIDENCE FOR GROWTH-HORMONE DEPENDENCE [J].
COHEN, KL ;
NISSLEY, SP .
ACTA ENDOCRINOLOGICA, 1976, 83 (02) :243-258